Home   Contact Palatin   Site Map  
 

Overview

Palatin Technologies (AMEX:PTN) is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific peptide and small molecule therapeutics. Our proprietary drug development pipeline is based primarily on melanocortin (“MC”)-based therapeutics, and we believe we are a leader in this area of pharmaceutical research and development. Therapeutics affecting the activity of the MC family of receptors may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia, hemorrhagic shock and inflammation-related diseases. We are exploring other receptor-specific therapeutics, including natriuretic peptide receptor A agonist compounds for use in treatment of acute systemic hypertension, congestive heart failure and other cardiovascular diseases. Palatin has entered into collaborations with industry leaders AstraZeneca and the Mallinckrodt division of Covidien (NYSE:COV).

Product Portfolio

  • Bremelanotide, a peptide-based melanocortin receptor agonist, for treatment of hemorrhagic shock (shock induced by blood loss, such as secondary to surgery or trauma) and related indications
  • PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of acute system hypertension
  • PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of acute congestive heart failure
  • PL-6983, a novel and specific peptide-based melanocortin-4 receptor agonist, for treatment of male and female sexual dysfunction without blood pressure increases seen with bremelanotide
  • Ongoing licensing and research collaboration with AstraZeneca AB on melanocortin receptor-based compounds for treating obesity and related indications
  • NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection, is the subject of a strategic collaboration agreement with the Mallinckrodt division of Covidien.  In December 2005, the Company and Mallinckrodt voluntarily suspended the sales, marketing and distribution of NeutroSpec.  All ongoing clinical trials and regulatory approvals of NeutroSpec have been suspended while the Company and Mallinckrodt evaluate future development and marketing activities involving NeutroSpec.